Brokerages Set Vir Biotechnology, Inc. (NASDAQ:VIR) Price Target at $17.30

Vir Biotechnology, Inc. (NASDAQ:VIR) has been assigned an average rating of “Moderate Buy” from the eleven research firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $17.30.

VIR has been the topic of several research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Monday, December 22nd. HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Vir Biotechnology in a research report on Tuesday.

Insiders Place Their Bets

In other news, major shareholder Endurance (Cayman) Ltd Svf sold 191,854 shares of the stock in a transaction on Monday, December 1st. The stock was sold at an average price of $5.98, for a total value of $1,147,286.92. Following the sale, the insider directly owned 13,728,924 shares in the company, valued at approximately $82,098,965.52. This trade represents a 1.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Vicki L. Sato sold 22,000 shares of Vir Biotechnology stock in a transaction on Monday, December 1st. The shares were sold at an average price of $6.00, for a total value of $132,000.00. Following the completion of the transaction, the director owned 1,188,391 shares of the company’s stock, valued at approximately $7,130,346. This trade represents a 1.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 2,559,324 shares of company stock worth $15,659,663 in the last ninety days. 16.00% of the stock is owned by corporate insiders.

Institutional Trading of Vir Biotechnology

A number of large investors have recently made changes to their positions in VIR. FNY Investment Advisers LLC acquired a new stake in shares of Vir Biotechnology in the 3rd quarter valued at $38,000. Raymond James Financial Inc. acquired a new position in shares of Vir Biotechnology during the 2nd quarter worth about $35,000. Federated Hermes Inc. raised its position in shares of Vir Biotechnology by 153.8% during the 3rd quarter. Federated Hermes Inc. now owns 8,085 shares of the company’s stock worth $46,000 after acquiring an additional 4,899 shares in the last quarter. Apollon Wealth Management LLC purchased a new stake in Vir Biotechnology during the second quarter worth approximately $50,000. Finally, Truist Financial Corp acquired a new position in Vir Biotechnology in the third quarter valued at approximately $63,000. 65.32% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Vir Biotechnology

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: HC Wainwright raised EPS estimates across multiple quarters and fiscal years (Q4 2025, Q1–Q4 2026, FY2025–FY2029), trimming expected losses (FY2026 now -$2.16 vs prior -$2.40) and kept a Buy rating and $15 target — this suggests analysts see improving operating trends and provides a bullish price benchmark. MarketBeat: VIR coverage
• Neutral Sentiment: The upgrades narrow projected losses but consensus still implies multi‑year negative EPS (current consensus ~-3.92 FY). The changes signal gradually improving expectations rather than an immediate profitability inflection. MarketBeat: VIR coverage
• Negative Sentiment: Fundamentals remain a constraint: Vir missed Q3/Q4 earnings (Nov. 5) with a larger-than-expected loss and very low revenue ($0.24M), negative margins and negative ROE — these factors, plus limited near‑term commercial revenue and ongoing R&D spend, are likely keeping the stock under pressure. MarketBeat: VIR coverage

Vir Biotechnology Stock Performance

Vir Biotechnology stock opened at $5.94 on Monday. The company has a market capitalization of $826.37 million, a PE ratio of -1.65 and a beta of 1.39. Vir Biotechnology has a fifty-two week low of $4.16 and a fifty-two week high of $14.45. The firm has a 50 day moving average price of $5.99 and a 200 day moving average price of $5.52.

Vir Biotechnology (NASDAQ:VIR) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($1.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.47). Vir Biotechnology had a negative return on equity of 50.76% and a negative net margin of 2,963.54%.The firm had revenue of $0.24 million for the quarter, compared to analyst estimates of $1.98 million. During the same quarter last year, the company earned ($1.56) earnings per share. The firm’s revenue for the quarter was up .8% on a year-over-year basis. As a group, equities research analysts forecast that Vir Biotechnology will post -3.92 earnings per share for the current year.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.